Erytech Pharma S.A. (Euronext Paris: ERYP, Nasdaq: ERYP)

https://www.erytech.com

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in acute lymphoblastic leukemia was recently completed in the Nordic countries of Europe. Eryaspase is not approved in any country. ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. *

	Start	2004-01-01 established
	Group	Erytech (Group)
	Industry	Graspa®
	Industry 2	Erycaps® platform
	Person	Beyen, Gil (Erytech 2012– CEO before TiGenix 201112 CBO + before CEO + Co-founder)
	Person 2	Soyer, Eric (Erytech 201509– CFO + COO before EDAP-TMS)

	Region	Lyon
	Country	France
	Street	60 avenue Rockefeller Bâtiment Adénine
	City	69008 Lyon
	Tel	+33-4-7874-4438
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2014-10-22)
	Currency	EUR
	Cash	165,400,000 (2018-06-30)

		* Document for »About Section«: Erytech Pharma. (1/4/21). "Press Release: Erytech to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event". Lyon & Cambridge, MA.

		Record changed: 2024-02-12